Dicerna Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to utilize ribonucleic acid interference to silence selectively genes that cause or contribute to disease. Nedosiran is Co.'s investigational product candidate for the treatment of primary hyperoxaluria (PH) type 1, PH type 2, and PH type 3. Co.'s GalXC product candidate, RG6346, is for the treatment of chronic hepatitis B virus (HBV) infection. Therapies for HBV include nucleoside analogs and pegylated interferon regimens. Co.'s another GalXC product candidate, belcesiran, is for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. The DRNA average annual return since 2014 is shown above.
The Average Annual Return on the DRNA average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DRNA average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DRNA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|